Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01477411 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study of Digoxin and PA21
A Phase 1 study, sponsored by Vifor Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT01477411 is a Phase 1 study that has completed, run by Vifor Pharma. The registered enrollment target is 42 participants.
The verdict
NCT01477411, a Phase 1 study, has completed, sponsored by Vifor Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Digoxin is affected by PA21.
Interventions
- DRUG Digoxin
- DRUG PA21
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01477411
The ClinicalTrials.gov registry entry for NCT01477411 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vifor Pharma, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Digoxin is the first listed.
NCT01477411 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01477411 about?
NCT01477411 is a clinical study titled "A Drug-Drug Interaction Study of Digoxin and PA21". The purpose of this study is to determine if Digoxin is affected by PA21.
What is the current status of trial NCT01477411?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2011-11. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01477411?
The interventions under investigation include: Digoxin (DRUG), PA21 (DRUG).
Who is sponsoring clinical trial NCT01477411?
This trial is sponsored by Vifor Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.